Form 4 for SPRY ARS Pharmaceuticals, Inc.
Accepted 2026-06-12 20:04:44 ET · period of report 2026-06-12 · accession 0001398595-26-000004 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| T | 2026-06-12 20:04 | 2026-06-12 | SPRY | Fitzpatrick Alexander A | CLO | S - Sale | $10.00 | -3,355 | 90.9K | -4% | -$33.5K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-06-12 | S | D | 3,355 | $10.00 | 90,910 | D | — | — | (F1) The shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 5, 2025. (F2) Includes 2,907 shares acquired under the Issuer's 2020 Employee Stock Purchase Plan (the "ESPP") on June 30, 2025 and 1,745 shares acquired under the ESPP on December 31, 2025. |